Fig. 1
From: Melatonin and urological cancers: a new therapeutic approach
Melatonin (a) promotes apoptosis in prostate cancer cells through activating TNF-α/TRAIL, JNK and P38 signaling pathways, and inhibiting SIRT1 pathway, (b) inhibits angiogenesis by inhibition of HIF-1/2α and VEGF expression and (C1) exerts anti-androgenic effects by inhibiting nuclear translocation of androgen receptor and (C2) MT1 receptor-dependent disruption of positive interaction between androgen receptor splice variant-7 (AR-V7) expression and NF-κB/IL-6 signaling